前列腺穿刺标本行 P504 s、P63、CK34βE12免疫组化检测的临床价值分析  

Clinical value of prostate needle biopsy specimens for P504s, P63, CK34 beta E12 immunohistochemistry de-tection

作　　者：翁亚菡 

机构地区：[1]河南省鹤壁市人民医院南院区病理科,458030

出　　处：《中国实用医刊》2016年第1期69-70,共2页Chinese Journal of Practical Medicine

摘　　要：目的：探讨前列腺穿刺标本行P504s、P63、CK34βE12免疫组化检测的临床价值。方法选取鹤壁市人民医院南院区2011年4月至2014年2月筛查的82例疑似前列腺癌患者穿刺标本，均采用SP法完成免疫组织化学染色，记录各标本Gleason组织学分级、评分结果及免疫组化检测结果。结果82例疑似前列腺癌穿刺标本中，确诊为前列腺癌者25例（30．5％），其中高分化腺癌3例（12．0％），中分化腺癌7例（28．0％），低／未分化癌15例（60．0％）；良性肿瘤57例（69．5％），其中前列腺上皮内瘤16例（28．1％），良性增生41例（71．9％）。前列腺癌患者P63和CK34βE12免疫组化染色结果呈阴性，P504 s免疫组化染色结果呈阳性，良性肿瘤或正常腺泡表示则相反。结论在前列腺病变诊断中采用P504s、P63、CK34βE12联合标记方案，可有效降低前列腺癌漏诊及误诊风险，值得临床推广。Objective To investigate the clinical value of prostate biopsy specimens for P504s, P63, CK34 beta E12 immunohistochemical detection.Methods Eighty-two patients with suspected prostate cancer from April 2011 to February 2014 were selected, the prostate needle biopsy specimens were taken SP immunohistochemical staining method , and then recorded the specimens of Gleason histological grading , scoring results and immunohistochemical results .Re-sults Eighty-two patients with suspected prostate cancer biopsy in diagnosis of prostate cancer in 25 cases （30.5%）, including 3 cases of high differentiated adenocarcinoma （ 12%） , 7 cases of moderately differentiated adenocarcinoma （28%）, low/undifferentiated carcinoma in 15 cases （60%）.Benign tumor in 57 cases （69.5%）, prostate intraepi-thelial neoplasia in 16 cases （28.1%）, 41 cases of benign hyperplasia （71.9%）.Prostate cancer patients with P63 and CK34 beta E12 immunohistochemical staining results were negative, P504s immunohistochemical staining results were positive, benign tumor and normal acini said on the contrary.Conclusions P504s, P63, CK34 beta E12 labeling scheme in diagnosis of prostate disease can reduce prostate cancer loss diagnosis and misdiagnosis , So it is worthy of clin-ical promotion.

关 键 词：前列腺癌 P504S P63 CK3417 E12 

分 类 号：R737.250.4[医药卫生—肿瘤]